ALK to accelerate launches of ODACTRA™ in the USA / ACARIZAX® in Canada
ALK announced the FDA has completed the transfer to ALK of the Biologics Licences for its tablet portfolio, including GRASTEK® and RAGWITEK® and the house dust mite SLIT-tablet ODACTRA™ (marketed as ACARIZAX® in Europe). August 21, 2017